PTGIR and pulmonary arterial hypertension: It selectively activates the prostaglandin-I2 receptor agonist, resulting in significant vasodilation.44 In the phase 3 GRIPHON study, selexipag at a dose of up to 1.6 mg twice daily reduced the risk of the primary composite endpoint of death or PAH-related complication.